Skip to Content
Accesswire

Scientific Industries Reports Financial Results for Third Quarter of Fiscal Year 2021

Benchtop Lab Equipment Reports Strong Revenues and Earnings

Company Continues to Invest In Its Bioprocessing Business

BOHEMIA, NY / ACCESSWIRE / May 17, 2021 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of optical sensors for non-invasive, real-time monitoring of cell culture systems through its subsidiary Scientific Bioprocessing, Inc. ("SBI"), today reported financial results for the third quarter of fiscal 2021 ended March 31, 2021.

2021 Third Quarter, Nine Months and Recent Highlights:

  • Net revenues were $2.5 million and $7.2 million, an increase of 17% and 16% vs. prior year.
  • Gross profit was $1.4 million and $3.8 million, an increase of 24% and 18% vs. prior year.
  • Gross profit percentage was 54.3% and 52.8%, an increase of 280 and 60 basis points vs. prior year.
  • Benchtop Laboratory Equipment Adjusted EBITDA (non-GAAP) was $0.80 and $1.8 million, an increase of 378% and 328% vs. prior year periods.
  • Cash and cash equivalents and investments as of March 31, 2021 was approximately $6.0 million and no long-term debt.
  • Acquired aquila biolabs GmbH ("aquila") in April 2021 to advance platform for digitally simplified bioprocessing.

Management Discussion

Helena Santos, Chief Executive Officer of Scientific Industries, stated, "We are pleased with the solid financial performance in our fiscal third quarter with double digit topline growth. With the continued strong performance of our core business plus the growth potential of our Bioprocessing Systems ("SBI"), especially with the recent acquisition of aquila in April 2021, the long-term outlook for our Company is truly exciting."

John Moore, Chairman of Scientific Industries and President of SBI, said, "We are positioning the Company for long-term success as we enter the $1.2 billion cell culture and biomanufacturing market. We are excited as we enter the next phase of development with our bioprocessing business to improve productivity gains and time-to-market. Our recent acquisition of aquila combined with our technology will allow us to create a new digital platform to precisely tune multiple culture parameters in real-time for the production of high-quality therapeutics."

2021 Third Quarter and Nine Months Financial Review

Net revenues for the third quarter of fiscal year 2021 were $2.5 million, an increase of $0.4 million, or 17%, compared to $2.1 million for the third quarter of fiscal year 2020. Gross profit for the fiscal third quarter was $1.4 million with a gross profit of 54.3%, an increase of $0.3 million, or 24% and 280 basis points compared to $1.1 million and 51.5% for the third quarter of fiscal 2020. Net loss for the fiscal third quarter was $1.4 million, or a loss of $(0.50) per basic share, compared to net loss of $0.31 million, or a loss of $(0.21) per basic share for the third quarter of fiscal 2020.

For the nine months ended March 31, 2021, the Company reported net revenues of $7.2 million, an increase of $1.0 million, or 16%, compared to $6.2 million for the nine months ended March 31, 2020. Gross profit for the nine-month period was $3.8 million with a gross profit percentage of 52.8%, an increase of $0.6 million, or 18% and 60 basis points, compared to $3.3 million and 52.2% for the nine-month period of 2020. Net loss for the nine months was $2.3 million, or $(0.81) loss per basic share, compared to a net loss of $0.4 million, or $(0.25) loss per basic share for the nine months ended March 31, 2020, respectively.

The Company benefited from another consecutive quarter of increased sales from its core Benchtop Laboratory Equipment Operations with continued robust worldwide demand for its vortexers and shakers, in part due to COVID-related research and testing. As a result, sales of the Benchtop Laboratory Equipment Operations increased by 31% and 28% for the three- and nine-month periods ended March 31, 2021 compared to the same periods last year, with significantly higher income from the segment's operations for both the current three and nine-month periods. Adjusted EBITDA for Benchtop Laboratory Equipment, a non-GAAP measure, for the three and nine-month periods was $0.80 million and $1.8 million, an increase of 378% and 328% over for the same prior year periods of $0.2 million and $0.4 million.

The Company's results reflected continued investment in the Company's Bioprocessing Systems operations, which resulted in increased operating expenses, including sales, marketing, and product development. In addition, the Company's results reflected non-cash stock options expense of $1.3 million and $1.4 million for the three- and nine-month periods ended March 31, 2021 compared to $14,600 and $50,000 for the prior year periods, respectively. The 2021 nine months' results also included losses from discontinued operations resulting from the November 30, 2020 sale of the Company's Catalyst Research Instruments Operations.

On April 29, 2021, the Company acquired aquila, a privately held German bioprocessing technology company for approximately $7.9 million financed in part through a private placement investment in the Company of approximately $7.6 million. This strategic acquisition provides the Company with the building blocks to create a new category in bioprocessing called digitally simplified bioprocessing.

Despite the significant investment in SBI, the Company ended the quarter with $6.0 million in cash and cash equivalents and short-term investments, in part due to the robust sales and profits generated by its core business segment - Benchtop Laboratory Equipment, and to a lesser extent, a second Payroll Protection Program loan.

About Scientific Industries, Inc.

Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems and methods. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit www.scientificindustries.com.

About Scientific Bioprocessing, Inc.

SBI is dedicated to providing state-of-the-art instruments, strategies, and technologies to expedite the production of viable cells and therapies with a streamlined process and product consistency. SBI's mission is to develop sensor technologies and instruments that make cell culture and bioprocessing work easier, experiments more reproducible, and culture conditions better suited to meet experimental objectives. SBI is a subsidiary of Scientific Industries, Inc.To learn more, visit www.scientificbio.com.

Non-GAAP Measures

This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. Non-GAAP financial measures presented in this press release include Benchtop Laboratory Equipment Adjusted EBITDA. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies.

Safe Harbor Statement

Statements made in this press release that relate to future events, performance or financial results of the Company are forward-looking statements which involve uncertainties that could cause actual events, performance or results to materially differ. The Company undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statement should be read in conjunction with the additional information about risks and uncertainties set forth in the Company's Securities and Exchange Commission reports, including our annual report on Form 10-K.

Contact:

Helena Santos
CEO and President
Phone: 631-567-4700
info@scientificindustries.com

Investor Contact:

Joe Dorame
Lytham Partners, LLC
Phone: (602) 889-9700
SCND@lythampartners.com

--FINANCIAL TABLES FOLLOW-

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

ASSETS
March 31, 2021
Cash and Cash Equivalents $ 627,500
Investment Securities 5,325,700
Other Current Assets 5,231,200
Deferred Taxes 1,189,400
Other Long-Term Assets 1,526,500
Total Assets $ 13,900,300
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities $ 1,858,500
Long-Term Liabilities 1,199,400
Shareholders' Equity 10,842,400
Total Shareholders' Equity & Liabilities $ 13,900,300

SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Month Periods Ended For the Nine Month Periods Ended
March 31, March 31,
2021 2020 2021 2020
Revenues $ 2,508,600 $2,136,200 $7,245,100 $6,234,500
Gross Profit 1,362,900 1,099,200 3,825,700 3,255,600
Operating Expenses 3,221,700 1,334,200 6,124,600 3,314,400
Loss from Operations (1,858,800) (235,00) (2,298,900) (58,800)
Total Other Income (expense), Net 28,600 (41,900) 93,700 (30,100)
Loss Before Income Tax (Benefit) (1,830,200) (276,900) (2,205,200) (88,900)
Income Tax (Benefit) (378,200) (45,500) (472,300) (15,000)
Net Loss from Continuing Operations (1,452,000) (231,400) (1,732,900) (73,900)
Income (Loss) From Discontinued Operations 16,400 (99,600) (758,400) (360,300)
Income Tax (Benefits) - (16,400) (179,900) (67,000)
Net Income (Loss) from Discontinued
Operations 16,400 (83,200) (578,500) (293,300)
Net Loss $(1,435,600) $(314,600) $(2,311,400) $(367,200)
Basic earnings per common share:
Continuing Operations $(0.51) $(0.15) $(0.61) $(0.05)
Discontinued Operations $0.01 $(0.06) $(0.20) $(0.20)
Consolidated Operations $(0.50) $(0.21) $(0.81) $(0.25)
Weighted average number of outstanding shares:
Basic 2,861,607 1,502,773 2,861,376 1,497,567

SOURCE: Scientific Industries, Inc.



View source version on accesswire.com:
https://www.accesswire.com/647831/Scientific-Industries-Reports-Financial-Results-for-Third-Quarter-of-Fiscal-Year-2021

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.